IVIg for relapsing–remitting multiple sclerosis: promises and uncertainties. (July 2015)

• Record Type: Journal Article
• Authors: Bayry, Jagadeesh; Hartung, Hans-Peter; Kaveri, Srini V.
• Is Part Of: Trends in pharmacological sciences. Volume 36:Number 7(2015)
• Page Start: 419
• Page End: 421
• Publication Date: 2015-07
• Subjects: Pharmacology -- Periodicals; Pharmacology -- trends -- Periodicals; Pharmacologie -- Périodiques; Pharmacology; Electronic journals; Periodicals; 615.1
• DOI: 10.1016/j.tips.2015.04.012
• Languages: English
• ISSNs: 0165-6147

Abstract

<abstract abstract-type="author" id="abs0005"> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p id="spar0005">Despite promising clinical trials, intravenous immunoglobulin (IVIg) therapy in relapsing–remitting multiple sclerosis (MS) has met with uncertainties that might be attributed to small patient cohorts, heterogeneity in the patients, dose of IVIg, or the duration and window of treatment.</p> </sec> </abstract>